Does Rallies show 13F holders for CVKD?

Yes. Rallies tracks hedge fund and 13F ownership data for CVKD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CVKD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CVKD. It does not provide personalized investment advice.

CVKD (Cadrenal Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a publicly traded Healthcare sector company. As of May 21, 2026, CVKD trades at $5.16 with a market cap of $14.84M and a P/E ratio of -0.78. CVKD moved +0.00% today. Year to date, CVKD is -29.51%; over the trailing twelve months it is -67.09%. Its 52-week range spans $4.21 to $22.90. Analyst consensus is buy with an average price target of $29.00. Rallies surfaces CVKD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CVKD stock?

Hedge funds tracked by Rallies that own CVKD include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cadrenal Therapeutics, Inc. Common Stock.

CVKD Key Metrics

Key financial metrics for CVKD
Metric	Value
Price	$5.16
Market Cap	$14.84M
P/E Ratio	-0.78
EPS	$-6.64
Dividend Yield	0.00%
52-Week High	$22.90
52-Week Low	$4.21
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-13.24M
Gross Margin	0.00%

Top Hedge Funds Holding CVKD

Renaissance Technologies holds 59.49K shares of CVKD, changed -59.84% as of Jun 30, 2024.
Citadel Advisors holds 54.54K shares of CVKD, changed -2.34% as of Jun 30, 2024.

Latest CVKD News

Cadrenal’s CAD-1005 Improves Glycemic Control in Obesity Models, Reduces HIT Thrombotic Events — Mar 12, 2026
Cadrenal’s CAD-1005 Cuts Thrombotic Events in Phase 2 HIT Ahead of FDA Meeting — Mar 2, 2026
Cadrenal Phase 2 HIT Trial Shows 25% Reduction in Thrombotic Events — Feb 24, 2026

Recent CVKD Insider Trades

Szot Matthew K sold 9.93K (~$69.23K) on Dec 29, 2025.
Szot Matthew K sold 1.80K (~$25.18K) on Oct 27, 2025.
Pham Quang X sold 1.31K (~$18.40K) on Oct 27, 2025.

CVKD Analyst Consensus

2 analysts cover CVKD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.00.

Common questions about CVKD

Who owns CVKD stock?: Hedge funds tracked by Rallies that own CVKD include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cadrenal Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for CVKD?: Yes. Rallies tracks hedge fund and 13F ownership data for CVKD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CVKD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CVKD. It does not provide personalized investment advice.